Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis
Authors:
- 27 May 2012
- journal article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 20 (6) , 524-534
Abstract
In general, colon-specific delivery of a drug decreases systemic absorption and increases therapeutic concentration of the drug at the target site. N-succinylglutam-1 or 5-yl celecoxib (SG1C and SG5C) were prepared as a colon-specific prodrug of celecoxib, a selective Cox-2 inhibitor, and investigated whether the celecoxib derivatives could deliver celecoxib to the target site and improve cardiovascular toxicity and therapeutic effectiveness for the treatment of familiar adenomatous polyposis. SG1C and SA5C were cleaved to release celecoxib in the cecal contents while stable in small intestinal contents. The cecal release of celecoxib was much greater for SG1C than SG5C. SG1C administered orally was barely detected in the blood and urine. SG1C delivered much greater amount of celecoxib to the large intestine while keeping the plasma concentration of celecoxib at much lower level compared with oral administration of free celecoxib. Consistent with these pharmacokinetic results, SG1C supplied a greater concentration of celecoxib for the entire colonic tissue and did not change the serum level of 6-keto-PGF1α whose decrease is associated with the cardiovascular toxicity of celecoxib. Taken together, colon-specific delivery of celecoxib using a prodrug approach may be a useful strategy to improve toxicological and pharmacological properties of celecoxib.Keywords
This publication has 22 references indexed in Scilit:
- What should be considered on design of a colon-specific prodrug?Expert Opinion on Drug Delivery, 2010
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Risk of cardiovascular events and celecoxib: a systematic review and meta-analysisJournal of the Royal Society of Medicine, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Cardiovascular Risk Associated with CelecoxibNew England Journal of Medicine, 2005
- Coxibs and Cardiovascular DiseaseNew England Journal of Medicine, 2004
- Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In VivoCirculation, 2004
- Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?JACC, 2002
- Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposisExpert Opinion on Pharmacotherapy, 2001
- Gastrointestinal Parameters That Influence Oral MedicationsJournal of Pharmaceutical Sciences, 1993